[MCE] Breaking the Chains, Immune Checkpoint Inhibitory Antibodies Lead a New Chapter in Immunotherapy!

02 Apr [MCE] Breaking the Chains, Immune Checkpoint Inhibitory Antibodies Lead a New Chapter in Immunotherapy!

Tumor Immunotherapy During tumor development, immunotherapy inhibits highly expressed immune checkpoint molecules to restore T-cell recognition, thereby clearing or slowing tumor progression[1]. Immune Checkpoint Inhibitory Antibody Programmed cell death 1 (PD-1) is the T-cell immune checkpoint molecule of greatest interest. PD-1 or PD-L1 inhibitory antibodies upregulate T-cell activation and activate endogenous anti-tumor immune responses, thus exerting therapeutic effects on tumors[2]. Figure 1. The binding of PD-L1 to PD-1 prevents T cells from killing tumor cells in the body (left panel). Immune checkpoint inhibitory antibodies (anti-PD-L1 or anti-PD-1) block the binding of PD-L1 to PD-1, allowing T cells to kill tumor cells (right panel)[1]. MedChemExpress Products Product Name Specices Target Isotype Anti-Mouse PD-L1 Antibody Mouse PD-L1 IgG2b Anti-Mouse PD-1 Antibody Mouse PD-1 IgG1 Trastuzumab Human HER2 IgG1 Ipilimumab Human CTLA-4 IgG1κ Cetuximab Human EGFR IgG1 Adalimumab Human TNF-α IgG1 MCE Inhibitory Antibodies are research-grade biosimilar control antibodies with the same active biological components as the original therapeutic antibody. Target proteins include PD-1, PD-L1, CD20, HER2, EGFR, VEGFR, TNF-α, etc., which are widely used in cancer, immunity, infection and other popular research fields. Reference: [1] Nat Rev Drug Discov. 2019 Mar;18(3):175-196. [2] Immunity. 2018 Mar 20;48(3):434-452. Request Your Quote